Abbott Laboratories (NYSE:ABT – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare Abbott Laboratories to related companies based on the strength of its valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and risk.
Profitability
This table compares Abbott Laboratories and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Abbott Laboratories | 9.75% | 18.04% | 9.09% |
| Abbott Laboratories Competitors | -191.34% | -187.68% | -21.85% |
Analyst Recommendations
This is a summary of recent ratings for Abbott Laboratories and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abbott Laboratories | 0 | 4 | 22 | 1 | 2.89 |
| Abbott Laboratories Competitors | 4328 | 10558 | 18358 | 840 | 2.46 |
Abbott Laboratories presently has a consensus target price of $119.04, suggesting a potential upside of 15.62%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.98%. Given Abbott Laboratories’ competitors higher possible upside, analysts clearly believe Abbott Laboratories has less favorable growth aspects than its competitors.
Dividends
Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.4%. Abbott Laboratories pays out 94.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.1% and pay out 40.5% of their earnings in the form of a dividend. Abbott Laboratories has raised its dividend for 54 consecutive years.
Valuation and Earnings
This table compares Abbott Laboratories and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Abbott Laboratories | $44.33 billion | $6.52 billion | 38.42 |
| Abbott Laboratories Competitors | $1.87 billion | $136.77 million | 5.94 |
Abbott Laboratories has higher revenue and earnings than its competitors. Abbott Laboratories is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Abbott Laboratories has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Abbott Laboratories’ competitors have a beta of 2.58, meaning that their average share price is 158% more volatile than the S&P 500.
Institutional and Insider Ownership
75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Abbott Laboratories beats its competitors on 11 of the 15 factors compared.
About Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
